There have been no clinically applicable changes in comparison to 2011 except for new information and new suggestions regarding the treatment method with bisphosphonates and denosumab (see area ‘Bisphosphonates and RANKL Antibody Denosumab’).Despite appreciable endeavours, the remedy for breast cancer awaits an even better understanding of the